Xeljanz and Hepatic function abnormal - a phase IV clinical study of FDA data

Summary:

Hepatic function abnormal is reported as a side effect among people who take Xeljanz (tofacitinib citrate), especially for people who are female, 60+ old, have been taking the drug for 1 - 2 years also take Methotrexate, and have Ulcerative colitis.

The phase IV clinical study analyzes which people have Hepatic function abnormal when taking Xeljanz. It is created by eHealthMe based on reports of 238,928 people who have side effects when taking Xeljanz from the FDA, and is updated regularly.

What is Xeljanz?

Xeljanz has active ingredients of tofacitinib citrate. It is often used in rheumatoid arthritis. eHealthMe is studying from 239,081 Xeljanz users. Check the latest studies of Xeljanz.

What is Hepatic function abnormal?

Hepatic function abnormal is found to be associated with 1,445 drugs and 2,016 conditions by eHealthMe. Check the latest studies of Hepatic function abnormal.

On May, 01, 2026

238,928 people reported to have side effects when taking Xeljanz.
Among them, 107 people (0.04%) have Hepatic function abnormal.

Could Xeljanz cause Hepatic function abnormal?

Among these 107 people:

How long have people been on Xeljanz when they have Hepatic function abnormal? *

Click here to view more results

What is the gender of people who have Hepatic function abnormal when taking Xeljanz? *

Click here to view

What is the age of people who have Hepatic function abnormal when taking Xeljanz? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Xeljanz and have Hepatic function abnormal?

- Check whether Hepatic function abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Xeljanz:

Xeljanz (239,081 reports)

Hepatic function abnormal treatments and more:

Hepatic function abnormal (47,051 reports)

How severe was Hepatic function abnormal and when was it recovered:

Hepatic function abnormal in Xeljanz

Expand to all the drugs that have ingredients of tofacitinib citrate:

Hepatic function abnormal and drugs with ingredients of tofacitinib citrate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Xeljanz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatic function abnormal:

Hepatic function abnormal (1,445 drugs)

Browse all the conditions that are associated with Hepatic function abnormal:

Hepatic function abnormal (2,016 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tofacitinib citrate (the active ingredients of Xeljanz) and Xeljanz (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.